NCT00010387View on ClinicalTrials.gov

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

August 31, 2007

Conditions
Anemia, Hemolytic, AutoimmuneFelty SyndromePurpura, ThrombocytopenicAutoimmune Diseases
Interventions
DRUG

cyclophosphamide

DRUG

filgrastim

Trial Locations (1)

21231

Johns Hopkins Oncology Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT00010387 - Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease | Biotech Hunter | Biotech Hunter